Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 181 to 195 of 916 results for death

  1. Palforzia for treating peanut allergy in children and young people (TA769)

    Evidence-based recommendations on Palforzia for treating peanut allergy in children and young people.

  2. MiraQ for assessing graft flow during coronary artery bypass graft surgery (MTG8)

    Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery.

  3. Velmanase alfa for treating alpha-mannosidosis (HST29)

    Evidence-based recommendations on velmanase alfa (Lamzede) for treating alpha-mannosidosis in people under 18 years and in people who turn 18 while on treatment.

  4. Chronic heart failure in adults: diagnosis and management (NG106)

    This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.

  5. Postnatal care (NG194)

    This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.

  6. Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)

    Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.

  7. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)

    Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.

  8. Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)

    Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma in adults.

  9. Everolimus for preventing organ rejection in liver transplantation (TA348)

    Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.

  10. Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

    Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.

  11. Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

    Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.

  12. The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)

    NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system

  13. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease (IPG593)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure in people with motor neurone disease. This involves implanting electrodes into the diaphragm to make it contract. This gradually strengthens the diaphragm and may eventually help the person to breathe without a ventilator.

  14. Therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury (IPG347)

    Evidence-based recommendations on therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury. This involves cooling either the baby's head or whole body to prevent brain damage.